Mohseni Mohammad-Javad, Aryan Zahra, Emamzadeh-Fard Sahra, Paydary Koosha, Mofid Vahid, Joudaki Hasan, Kajbafzadeh Abdol-Mohammad
Pediatric Urology Research Center, Pediatric Center of excellence, Tehran University of Medical Sciences, Tehran, Iran.
Research and Development Laboratory of Pegah Milk Industry, Iran Dairy Industries Company, Tehran, Iran.
Iran J Pediatr. 2013 Aug;23(4):430-8.
We examined the preventive effect of probiotic and antibiotics versus antibiotics alone, in children with recurrent urinary tract infections (RUTI) in a preliminary randomized clinical trial.
Between March 2007 and April 2011, children with the history of RUTI and unilateral vesicoureteral reflux (VUR) were randomly assigned to receive concomitant probiotic and antibiotics (Lactobacillus acidophilus and bifidobacterium lactis, 10(7)/ml, as 0.25 ml/kg three times a day regimen in addition to Nitrofurantoin, 1mg/kg daily (group I). In group II, all children received conventional prophylactic antibiotics alone (Nitrofurantoin, 1 mg/kg daily). Randomization was performed via using the random numerals table in a 1:1 manner with stratification by sex, age and grade of reflux. The urine examinations were done monthly and the incidence of UTI was evaluated in these two groups.
Forty-one children (age: 8.3±3.1 years) in group I and 44 children (age: 8.0±3.0 years) in group II were compared. During the course of three years, 39% in group I and 50% of participants in group II experienced RUTIs (P=0.4). Incidences of UTI - febrile and afebrile - reduced in both groups without any significant differences after two years of prophylaxis. Also, incidence of afebrile UTIs did not significantly differ (0.51±1.30 and 0.81±1.41 respectively, P =0.3); however, the incidence of febrile UTIs in particular were lower in group I (0.00±0.00 versus 0.13±0.40, P =0.03) in the last year.
The consumption of probiotic and antibiotics in children with RUTI is safe and more effective in reducing the incidence of febrile UTI in comparison to prophylactic antibiotics alone.
在一项初步随机临床试验中,我们研究了益生菌联合抗生素与单独使用抗生素相比,对复发性尿路感染(RUTI)儿童的预防效果。
2007年3月至2011年4月期间,有RUTI病史且伴有单侧膀胱输尿管反流(VUR)的儿童被随机分配接受益生菌联合抗生素治疗(嗜酸乳杆菌和双歧杆菌,10⁷/ml,每天0.25 ml/kg,分三次给药,同时服用呋喃妥因,每天1mg/kg,第一组)。在第二组中,所有儿童仅接受常规预防性抗生素治疗(呋喃妥因,每天1mg/kg)。通过使用随机数字表以1:1的方式进行随机分组,并按性别、年龄和反流程度进行分层。每月进行尿液检查,并评估这两组的UTI发生率。
比较了第一组的41名儿童(年龄:8.3±3.1岁)和第二组的44名儿童(年龄:8.0±3.0岁)。在三年的疗程中,第一组39%的参与者和第二组50%的参与者经历了RUTI(P = 0.4)。在预防两年后,两组的发热性和非发热性UTI发生率均有所降低,但无显著差异。此外,非发热性UTI的发生率也无显著差异(分别为0.51±1.30和0.81±1.41,P = 0.3);然而,特别是在最后一年,第一组的发热性UTI发生率较低(分别为0.00±0.00和0.13±0.40,P = 0.03)。
与单独使用预防性抗生素相比,RUTI儿童同时服用益生菌和抗生素是安全的,并且在降低发热性UTI发生率方面更有效。